Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 1

January 13, 2021
Supplements, Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 1, Volume 1, Issue 1

Partner | Cancer Centers | <b>UCSF Helen Diller Family Comprehensive Cancer Center</b>

This publication includes a summary of data on recent therapeutic advances in treating metastatic HER2-positive breast cancer that was presented during a series of 4 live regional broadcasts across the United States (California, Illinois, Texas, and Washington). Medical oncologists specializing in the treatment of breast cancer across those regions provide key insights on factors that influence planning and treatment selection.

download issueDownload Issue : Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 1

x